The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Myeloma: impact of Del 17p on transplantation outcomes
The high-risk abnormality del(17p) has a negative prognostic impact in patients with multiple myeloma. In this video, Morie Gertz, MD, MACP, Mayo Clinic College of Medicine, Rochester, MN, outlines the outcomes of multiple myeloma patients with Del 17p undergoing autologous stem cell transplantation. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
